Treatment of relapsed and refractory Hodgkin Lymphoma

Seminars in Hematology

Volumn 53, Issue 3, 2016, Pages 180-185

  von Tresckow, Bastian ^a   Moskowitz, Craig H ^b,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autologous stem cell transplant; Brentuximab vedotin; High dose chemotherapy; Hodgkin lymphoma; Relapse

Indexed keywords

BRENTUXIMAB VEDOTIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; PLATINUM COMPLEX; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; MAINTENANCE THERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SALVAGE THERAPY; TREATMENT PLANNING; CLINICAL TRIAL (TOPIC); HEMATOPOIETIC STEM CELL TRANSPLANTATION; RECURRENT DISEASE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; RECURRENCE; SALVAGE THERAPY;

EID: 84991207995     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2016.05.010     Document Type: Review

References (53)

1. [1] Engert, A., Plutschow, A., Eich, H.T., et al. Reduced treatment intensity in patients with early-stage Hodgkin׳s lymphoma. N Engl J Med 363:7 (2010), 640–652.
2. [2] von Tresckow, B., Plutschow, A., Fuchs, M., et al. Dose-intensification in early unfavorable Hodgkin׳s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:9 (2012), 907–913.
3. [3] Engert, A., Haverkamp, H., Kobe, C., et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin׳s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379:9828 (2012), 1791–1799.
4. [4] Gordon, L.I., Hong, F., Fisher, R.I., et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31:6 (2013), 684–691.
5. [5] von Tresckow, B., Engert, A., The role of autologous transplantation in Hodgkin lymphoma. Curr Hematol Malig Rep 6:3 (2011), 172–179.
6. [6] Morschhauser, F., Brice, P., Ferme, C., et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin׳s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 26:36 (2008), 5980–5987.
7. [7] Moskowitz, C.H., Nadamanee, A., Masszi, T., et al. The Aethera trial: results of a randomized, double-blind, placebo-controlled phase 3 study of brentuximab vedotin in the treatment of patients at risk of progression following autologous stem cell transplant for Hodgkin lymphoma. Abstract presented at Annual Meeting of the American Society of Hematology (ASH) Blood, 124(21), 2014, 673.
8. [8] Younes, A., Gopal, A.K., Smith, S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin׳s lymphoma. J Clin Oncol 30:18 (2012), 2183–2189.
9. [9] Linch, D.C., Winfield, D., Goldstone, A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin׳s disease: results of a BNLI randomised trial. Lancet 341:8852 (1993), 1051–1054.
10. [10] Schmitz, N., Pfistner, B., Sextro, M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin׳s disease: a randomised trial. Lancet 359:9323 (2002), 2065–2071.
11. [11] Rancea, M., Monsef, I., von Tresckow, B., Engert, A., Skoetz, N., High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database System Rev, 2013, 6 CD009411.
12. [12] Brice, P., Bouabdallah, R., Moreau, P., et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin׳s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 20:1 (1997), 21–26.
13. [13] Sureda, A., Constans, M., Iriondo, A., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin׳s lymphoma autografted after a first relapse. Ann Oncol 16:4 (2005), 625–633.
14. [14] von Tresckow, B., Moskowitz, C., Relapsed and refractory Hodgkin lymphoma. Engert, A., Younes, A., (eds.) Hodgkin lymphoma, 2015, Springer, 321–330.
15. [15] Moskowitz, C.H., Glassman, J.R., Wuest, D., et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 4:2 (1998), 311–316.
16. [16] Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97:3 (2001), 616–623.
17. [17] Josting, A., Rudolph, C., Reiser, M., et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin׳s disease. Ann Oncol 13:10 (2002), 1628–1635.
18. [18] Aparicio, J., Segura, A., Garcera, S., et al. ESHAP is an active regimen for relapsing Hodgkin׳s disease. Ann Oncol 10:5 (1999), 593–595.
19. [19] Sasse, S., Alram, M., Muller, H., et al. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leuk Lymphoma., 2015, 1–7.
20. [20] Josting, A., Muller, H., Borchmann, P., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin׳s lymphoma. J Clin Oncol 28:34 (2010), 5074–5080.
21. [21] Bartlett, N.L., Niedzwiecki, D., Johnson, J.L., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin׳s lymphoma: CALGB 59804. Ann Oncol 18:6 (2007), 1071–1079.
22. [22] Santoro, A., Magagnoli, M., Spina, M., et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin׳s lymphoma. Haematologica 92:1 (2007), 35–41.
23. [23] Kuruvilla, J., Nagy, T., Pintilie, M., Tsang, R., Keating, A., Crump, M., Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106:2 (2006), 353–360.
24. [24] Chen, R., Palmer, J.M., Martin, P., et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 21:12 (2015), 2136–2140.
25. [25] Moskowitz, A.J., Schoder, H., Yahalom, J., et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin׳s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 16:3 (2015), 284–292.
26. [26] LaCasce, A.S., Bociek, G., Sawas, A., et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood, 126(23), 2015, 3982.
27. [27] Garcia-Sanz, R., Sureda, A., Alonso-Alvarez, S., et al. Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood, 126(23), 2015, 582.
28. [28] Josting, A., Franklin, J., May, M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin׳s lymphoma registered in the database of the German Hodgkin׳s Lymphoma Study Group. J Clin Oncol 20:1 (2002), 221–230.
29. [29] Bröckelmann, P.J., Müller, H., Casasnovas, O., et al. Risk factors and a prognostic score for progression free survival after treatment with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin lymphoma (rrHL). Blood, 126(23), 2015, 1978.
30. [30] Moskowitz, A.J., Yahalom, J., Kewalramani, T., et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116:23 (2010), 4934–4937.
31. [31] Moskowitz, C.H., Matasar, M.J., Zelenetz, A.D., et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:7 (2012), 1665–1670.
32. [32] Devillier, R., Coso, D., Castagna, L., et al. Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy. Haematologica 97:7 (2012 Jul), 1073–1079, [#,63]?> http://dx.doi.org/10.3324/haematol.2011.056051. Epub 2012 Jan 22.
33. [33] Moskowitz, C.H., Nademanee, A., Masszi, T., et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin׳s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385:9980 (2015 May 9), 1853–1862, [#,63]?> http://dx.doi.org/10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.
34. [34] Sibon, D., Morschhauser, F., Resche-Rigon, M., et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica 101:4 (2016 Apr), 474–481, [#,63]?> http://dx.doi.org/10.3324/haematol.2015.136408. Epub 2015 Dec 31.
35. [35] Fung, H.C., Stiff, P., Schriber, J., et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 13:5 (2007), 594–600.
36. [36] Moskowitz, C.H., Yahalom, J., Zelenetz, A.D., et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 148:6 (2010), 890–897.
37. [37] Sweetenham, J., Walewski, J., Nademanee, A.P., et al. Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. Blood, 126(23), 2015, 3172.
38. [38] Santoro, A., Bredenfeld, H., Devizzi, L., et al. Gemcitabine in the treatment of refractory Hodgkin׳s disease: results of a multicenter phase II study. J Clin Oncol 18:13 (2000), 2615–2619.
39. [39] Devizzi, L., Santoro, A., Bonfante, V., et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin׳s disease. Ann Oncol 5:9 (1994), 817–820.
40. [40] Moskowitz, A.J., Hamlin, P.A. Jr., Perales, M.A., et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 31:4 (2013), 456–460.
41. [41] von Tresckow, B., Muller, H., Eichenauer, D.A., et al. Outcome and risk factors of Hodgkin Lymphoma patients who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 55:8 (2014), 1922–1924.
42. [42] Martinez, C., Canals, C., Sarina, B., et al. Identification of prognostic factors predicting outcome in Hodgkin׳s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 24:9 (2013), 2430–2434.
43. [43] Josting, A., Nogova, L., Franklin, J., et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin׳s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 23:7 (2005), 1522–1529.
44. [44] von Tresckow, B., Diehl, V., An update on emerging drugs for Hodgkin lymphoma. Exp Opin Emerg Drugs 19:2 (2014), 215–224.
45. [45] Chen, R., Gopal, A.K., Smith, S.E., et al. Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 126(23), 2015, 2736.
46. [46] Milpied, N., Fielding, A.K., Pearce, R.M., Ernst, P., Goldstone, A.H., Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin׳s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14:4 (1996), 1291–1296.
47. [47] Sureda, A., Robinson, S., Canals, C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin׳s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:3 (2008), 455–462.
48. [48] Peggs, K.S., Hunter, A., Chopra, R., et al. Clinical evidence of a graft-versus-Hodgkin׳s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365:9475 (2005), 1934–1941.
49. [49] Sureda, A., Canals, C., Arranz, R., et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin׳s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97:2 (2012), 310–317.
50. [50] Burroughs, L.M., O׳Donnell, P.V., Sandmaier, B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 14:11 (2008), 1279–1287.
51. [51] Raiola, A., Dominietto, A., Varaldo, R., et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin׳s lymphoma. Bone Marrow Transplant 49:2 (2014), 190–194.
52. [52] Chen, R., Palmer, J.M., Thomas, S.H., et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119:26 (2012), 6379–6381.
53. [53] Garciaz, S., Coso, D., Peyrade, F., et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin׳s lymphoma. Hematol Oncol 32:4 (2014), 187–191.